Has Shubham Pant, MD received payments from drug or device companies?

Yes. Drug and device makers reported $191,462 in general payments to Shubham Pant, MD across 127 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shubham Pant, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shubham Pant, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shubham Pant, MD

Hematology & Oncology · Houston, TXNPI 1831300318

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 30.1% of the total. 2025 is the largest year on record at $63,816, more than ten times the $781 reported in 2019. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$191,462in general payments, 2019–2025

Across 127 payments — averaging $1507.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ipsen Biopharmaceuticals, Inc$58K
Jazz Pharmaceuticals Inc.$37K
E.r. Squibb & Sons, L.L.C.$26K
Boehringer Ingelheim International GmbH$24K
USWM, LLC$14K
Merck$8K
plus $25K from 11 others

$7,203,721in research payments, 2019–2025

Across 364 payments — averaging $19,790 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$1.2M
Pfizer$1.1M
Merck$1M
Boehringer Ingelheim$892K
Incyte Corporation$593K
Biontech SE$548K
plus $1.9M from 15 others

What the payments were for

Consulting fees$95,76050%
Speaking & faculty fees$71,98138%
Travel & lodging$20,66711%
Food & beverage$3,0542%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ipsen Biopharmaceuticals, Inc	35	$57,653
Jazz Pharmaceuticals Inc.	28	$37,456
E.r. Squibb & Sons, L.L.C.	15	$25,761
Boehringer Ingelheim International GmbH	16	$23,523
USWM, LLC	2	$14,000
Merck	8	$8,384
Janssen Research & Development, LLC	9	$6,750
Novartis	1	$4,716
Pfizer	2	$3,738
EMD Serono Research & Development Institute, Inc.	1	$3,195
Daiichi Sankyo Inc.	2	$2,460
Boehringer Ingelheim	1	$2,220
Boehringer Ingelheim Pharma GmbH & Co.kg	2	$1,213
Trisalus Life Sciences, Inc.	2	$202
AstraZeneca	1	$129
Mirati Therapeutics, Inc.	1	$31
Octapharma USA, Inc.	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ONIVYDE$57,298
TAZVERIK$23,720
ZIIHERA$18,184
ZANIDATAMAB$11,900
SOMATULINE DEPOT$3,915
Enhertu$2,460
BRAFTOVI$1,788
KEYTRUDA$1,451
TRINAV INFUSION SYSTEM$202

How this compares

$191,462 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$52,122

Medicare patients

141

Services billed

385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prochlorperazine Maleate	34	$700
Ondansetron Hcl	44	$412

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Houston

Devesh PandyaHouston$1.8M
Elias JabbourHouston$1.3M
Naval DaverHouston$853K
Jorge Cortes-FrancoHouston$627K
Courtney DinardoHouston$478K
Prithviraj BoseHouston$463K
Milind JavleHouston$326K
Loretta NastoupilHouston$309K
Boyu HuHouston$281K
Luis CamachoHouston$276K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →